Invest in Mereo BioPharma Group plc on Stash

Mereo BioPharma Group PLC is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing new therapies for rare disease patients, focusing on bone/musculoskeletal, respiratory and endocrine indications. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, including BPS-804 (setrusumab) for the treatment of osteogenesis imperfecta (OI); MPH-966 (alvelestat) for the treatment of severe alpha-1 antitrypsin deficiency (AATD); BCT-197 (acumapimod) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD); BGS-649 (leflutrozole) for the treatment of hypogonadotropic hypogonadism (HH) in obese men; OMP-305B83 (navicixizumab) for the treatment of platinum-resistant ovarian cancer, and MPH-313 (etigilimab) for patients with advanced or metastatic solid tumors.

To buy fractional shares

of Mereo BioPharma Group plc stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Mereo BioPharma Group plc

Ticker: MREO

Mereo BioPharma Group plc

$0.53

+60.61%

(1W)

$

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years.

MREO Performance Breakdown

Share Price

$0.53

Today's change

8.14%

Year to date change (YTD)

-68.82%

Dividend yield

N/A

Last dividend paid

N/A

Last dividend pay date

N/A

About MREO

Mereo BioPharma Group PLC is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing new therapies for rare disease patients, focusing on bone/musculoskeletal, respiratory and endocrine indications. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, including BPS-804 (setrusumab) for the treatment of osteogenesis imperfecta (OI); MPH-966 (alvelestat) for the treatment of severe alpha-1 antitrypsin deficiency (AATD); BCT-197 (acumapimod) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD); BGS-649 (leflutrozole) for the treatment of hypogonadotropic hypogonadism (HH) in obese men; OMP-305B83 (navicixizumab) for the treatment of platinum-resistant ovarian cancer, and MPH-313 (etigilimab) for patients with advanced or metastatic solid tumors.

Mereo BioPharma Group plc Stock Ticker

MREO

For more information

https://www.mereobiopharma.com

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years.

Certain companies are volatile.

Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.

Why invest with Stash?

Fractional shares

Thousands of stocks and ETFs. No investing minimums.

Unlimited trades

Plus no add-on trading commission fees.

Diversification analysis

Custom investment recommendations can help you diversify.

Automatic investing

Dividend reinvestment,8 recurring investments, and more.

The Stock-Back® Card

We’ll give you matching stock in companies you shop at.1

Learn how to invest

Get professional advice and education at every step.

How to buy Mereo BioPharma Group plc stock on Stash

Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.

Stash offers three subscription plans: Stash Beginner, Stash Growth, and Stash+. Our Beginner plan starts at just $1 per month.

Once your market order of Mereo BioPharma Group plc stock is complete, you'll officially be a shareholder of Mereo BioPharma Group plc!

Invest in Mereo BioPharma Group plc on Stash

Mereo BioPharma Group PLC is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing new therapies for rare disease patients, focusing on bone/musculoskeletal, respiratory and endocrine indications. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, including BPS-804 (setrusumab) for the treatment of osteogenesis imperfecta (OI); MPH-966 (alvelestat) for the treatment of severe alpha-1 antitrypsin deficiency (AATD); BCT-197 (acumapimod) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD); BGS-649 (leflutrozole) for the treatment of hypogonadotropic hypogonadism (HH) in obese men; OMP-305B83 (navicixizumab) for the treatment of platinum-resistant ovarian cancer, and MPH-313 (etigilimab) for patients with advanced or metastatic solid tumors.

To buy fractional shares

of Mereo BioPharma Group plc stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Subscribe to The Wallet!

Looking for financial guidance? Check your Wallet. Every week, your inbox will be packed with market savviness and clever money management techniques. Sign up today!

By using this website you agree to our Terms of Use and Privacy Policy.

Ready to start
building wealth?

By using this website you agree to our Terms of Use and Privacy Policy.